CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.08
Equity-to-Asset	0.46
Debt-to-Equity	0.71
Debt-to-EBITDA	2.76
Interest Coverage	5.9
Piotroski F-Score	3/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	4.34	Distress Grey Safe
Beneish M-Score	-1.13	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	11.9
	3-Year EBITDA Growth Rate	6.3
	3-Year EPS without NRI Growth Rate	0.3
	3-Year FCF Growth Rate	-7.8
	3-Year Book Growth Rate	32.8
	Future 3-5Y EPS without NRI Growth Rate	15.01
	Future 3-5Y Total Revenue Growth Rate	12

Momentum Rank

8/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	8.33
	9-Day RSI	17.41
	14-Day RSI	25.64
	6-1 Month Momentum %	22.77
	12-1 Month Momentum %	-9.52

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.15
	Quick Ratio	0.97
	Cash Ratio	0.22
	Days Inventory	284.4
	Days Sales Outstanding	68.26
	Days Payable	110.92

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.41
	Dividend Payout Ratio	0.46
	3-Year Dividend Growth Rate	7.7
	Forward Dividend Yield %	1.41
	5-Year Yield-on-Cost %	2.26
	3-Year Average Share Buyback Ratio	-2
	Shareholder Yield %	-0.38

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	51.07
	Operating Margin %	18
	Net Margin %	17.62
	FCF Margin %	8.25
	ROE %	15.29
	ROA %	6.82
	ROIC %	6.45
	ROC (Joel Greenblatt) %	25.04
	ROCE %	11.07
	Years of Profitability over Past 10-Year	10

GF Value Rank

7/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	34.11
	Forward PE Ratio	30.22
	PE Ratio without NRI	34.11
	Shiller PE Ratio	44.52
	Price-to-Owner-Earnings	42.12
	PEG Ratio	4.55
	PS Ratio	6.24
	PB Ratio	5.03
	Price-to-Tangible-Book	122.29
	Price-to-Free-Cash-Flow	75.08
	Price-to-Operating-Cash-Flow	32.31
	EV-to-EBIT	27.24
	EV-to-Forward-EBIT	20.64
	EV-to-EBITDA	21.79
	EV-to-Forward-EBITDA	27.45
	EV-to-Revenue	6.81
	EV-to-Forward-Revenue	9.02
	EV-to-FCF	88.65
	Price-to-Projected-FCF	3.34
	Price-to-DCF (Earnings Based)	1.97
	Price-to-DCF (FCF Based)	5.15
	Price-to-Median-PS-Value	0.78
	Price-to-Peter-Lynch-Fair-Value	5.27
	Price-to-Graham-Number	13.78
	Earnings Yield (Greenblatt) %	3.67
	FCF Yield %	1.37
	Forward Rate of Return (Yacktman) %	8.7

GF Value: $100.58

CSLLY

Warning Signs

Warning! GuruFocus detected 5 Severe warning signs with CSLLY. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Data is updated daily.